A Bio-Techne Corporation (TECH - Free Report) brand, ProteinSimple, recently expanded the Ella immunoassay platform through the launch of a 32x4 Simple Plex cartridge. The cartridge provides more accurate results at a lower cost. Notably, ProteinSimple falls under the Protein Platforms division of Bio-Techne.
Simple Plex immunoassays have the same features as the "gold standard" ELISA and run on the fully-automated Ella platform. The Simple Plex cartridges in combination with the automated Ella platform have helped skip the manual steps and provide more accurate and dynamic 4-5 logs than traditional ELISAs in an hour.
Per management, the combination delivers solutions that enable higher throughput immunoassays.
In the last reported fourth quarter, Bio-Techne witnessed 22% year-over-year revenue growth (up 24% organically) at the Protein Platforms division. Notably, this quarter marked the sixth straight quarter of double-digit organic growth. Per management, growth was driven by new product introduction and applications.
The company is presently focusing on strengthening its position in this segment banking on the solid prospects. According to a report by Markets and Markets, the global immunoassay market is expected to reach a value of $25.45 billion by 2021, at a CAGR of 8.2% from 2016 to 2021. Considering the opportunities, we see the latest development as a strategic one.
However, the company faces tough competition in the industry from well-established players like Thermo Fisher Scientific Inc. (TMO - Free Report) , Luminex Corporation and Bio-Rad Laboratories, Inc. (BIO - Free Report) .
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
A Bio-Techne Corporation (TECH - Free Report) brand, ProteinSimple, recently expanded the Ella immunoassay platform through the launch of a 32x4 Simple Plex cartridge. The cartridge provides more accurate results at a lower cost. Notably, ProteinSimple falls under the Protein Platforms division of Bio-Techne.
Simple Plex immunoassays have the same features as the "gold standard" ELISA and run on the fully-automated Ella platform. The Simple Plex cartridges in combination with the automated Ella platform have helped skip the manual steps and provide more accurate and dynamic 4-5 logs than traditional ELISAs in an hour.
Per management, the combination delivers solutions that enable higher throughput immunoassays.
In the last reported fourth quarter, Bio-Techne witnessed 22% year-over-year revenue growth (up 24% organically) at the Protein Platforms division. Notably, this quarter marked the sixth straight quarter of double-digit organic growth. Per management, growth was driven by new product introduction and applications.
The company is presently focusing on strengthening its position in this segment banking on the solid prospects. According to a report by Markets and Markets, the global immunoassay market is expected to reach a value of $25.45 billion by 2021, at a CAGR of 8.2% from 2016 to 2021. Considering the opportunities, we see the latest development as a strategic one.
However, the company faces tough competition in the industry from well-established players like Thermo Fisher Scientific Inc. (TMO - Free Report) , Luminex Corporation and Bio-Rad Laboratories, Inc. (BIO - Free Report) .
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on TMO - FREE
Get the latest research report on BIO - FREE
Get the latest research report on TECH - FREE